Matarin Capital Management’s Travere Therapeutics TVTX Stock Holding History

Matarin Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.32M	Buy	48,372 +36,884	+321%	+$861K	0.32%	130
2020 Q3	$212K	Buy	+11,488	New	+$223K	0.04%	193
2018 Q2	–	Sell	-22,632	Closed	-$506K	–	326
2018 Q1	$506K	Sell	22,632 -2,723	-11%	-$64.8K	0.04%	246
2017 Q4	$534K	Hold	25,355	–	–	0.04%	244
2017 Q3	$631K	Hold	25,355	–	–	0.05%	227
2017 Q2	$492K	Buy	25,355 +2,333	+10%	+$42.3K	0.05%	223
2017 Q1	$425K	Buy	+23,022	New	+$450K	0.04%	230

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Matarin Capital Management's TVTX Position: Q4 2020 in Review

Matarin Capital Management increased its Travere Therapeutics (TVTX) stake by 321% in Q4 2020, buying an estimated $861K and bringing the position to 48,372 shares worth $1.32M. The position accounts for 0.32% of the portfolio, ranked #130.

Matarin Capital Management first reported a position in TVTX in Q1 2017 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold TVTX as of Q4 2020.

Matarin Capital Management held 48,372 shares of Travere Therapeutics worth $1.32M as of Q4 2020.
Matarin Capital Management bought 36,884 Travere Therapeutics shares in Q4 2020, an estimated $861K.
Travere Therapeutics made up 0.32% of Matarin Capital Management's portfolio in Q4 2020, its #130 holding.
Matarin Capital Management first reported a position in Travere Therapeutics in Q1 2017 and has held it in 7 quarters since.
138 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.